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Abstract 
Background: Bibliometric indicators, based on measuring patterns of publications and citations, are widely used by 
universities and research funders to assess research performance. Our aims were to: (1) perform a bibliometric analysis 
of UK macular disease research publications from 2011 to 2014 and compare this with the other countries producing 
major output in the area, and (2) compare the pattern of UK macular disease publication with the priorities for age-
related macular degeneration (AMD) developed by the Sight Loss and Vision Priority Setting Partnership (SLV-PSP).
Methods: We used the Scopus database to retrieve macular disease articles published from 2011 to 2014. Citations 
to articles from 2011 to 2013 and journal impact factors (JIFs) for 2014 articles were obtained. Articles with UK authors 
were allocated to the 10 SLV-PSP priorities for age-related macular degeneration (AMD), where possible.
Results: The UK, USA, and Germany and China were the top four producers of macular disease research from 2011 
to 2013. All except China had a higher proportion of citations than articles. There were 421 articles with UK authors 
published from 2011 to 2014, of which 49 % had international collaborators. The UK produced 9.7 % of the world’s 
output of macular disease articles from 2011 to 2013, but received 14.2 % of the world’s share of citations. UK authors’ 
share of the world’s top 10 % of cited publications from 2011 to 2013 was 16.2 %. In 2014, 13.2 % of UK articles were 
in journals in the top 10 % when ranked by Journal Impact Factors (JIFs), while the overall UK article share for that year 
was 9.9 %. UK articles did not show a strong correlation between citations and JIFs. The SLV-PSP published a set of 10 
priorities for research into age-related macular degeneration in October 2103. Only 8 % of the UK’s 2011–2014 publi-
cations matched the SLV-PSP top priority (treatment to stop dry AMD progressing) and 34 % did not match any of the 
SLV-PSP priorities, mainly because the priorities did not include invasive treatment of wet AMD.
Conclusions: The UK is performing well in macular research, based on bibliometric indicators. The distribution of 
past research topics does not match the priorities set by the SLV-PSP.
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Background
Macular disease is a major cause of morbidity in the UK. 
Age-related macular degeneration (AMD) is the com-
monest cause of visual loss in people aged over 65. Owen 
and colleagues have estimated the UK prevalence and 
incidence of late AMD, in the population aged 50 and 
over, at 2.4 % in 2007–2009 [1]. The prevalence increased 
to 4.8 % in those aged 65 years or more. They estimated 
that in 2020 the number of AMD cases will be 679,000.
Hereditary retinal dystrophies, including Stargardt dis-
ease, were the commonest single cause of visual loss in 
working age adults in 2009–2010, accounting for 20.2 % 
of blindness certifications in people of working age in 
England and Wales [2].
There have been recent advances in treatment of wet 
(neovascular) AMD but not in dry AMD or Stargardts 
and more research is needed. The Sight Loss and Vision 
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Priority Setting Partnership (SLV-PSP) developed a “top 
10” list of research priorities for AMD in 2013 [3].
Bibliometric measures of research performance
Bibliometric indicators are based on measuring patterns 
of authorship, publication and citations, and are widely 
used to evaluate the research performance of research-
ers (both individually and as a group) and of institutions. 
Such indicators form a key part of the global ranking and 
league tables which are important to Universities. For 
example, one such ranking, the Times Higher Education 
(THE) World University Rankings 2015–16, used 13 per-
formance indicators, grouped into five areas [4]. Research 
influence, measured by citations, is weighted at 30 per-
cent of the overall score. Another indicator was research 
productivity, accounting for 6 % of the overall score. This 
is based on a count of the number of papers per person 
(scaled for institutional size and normalised for subject) 
which were indexed in peer-reviewed journals in Else-
vier’s Scopus database. Another indicator, accounting 
for 2.5  % of the total score, is international collabora-
tion; that is, the proportion of a university’s total research 
journal publications that have at least one international 
co-author.
Rather than looking at citations to the total output 
of a department, institution or country, some evalua-
tions judge the quality of research based on the number 
of highly-cited papers produced. This is based on the 
assumption that the most highly-cited articles are likely 
to have made the greatest contribution within their field, 
or to be about important innovations. Highly cited is var-
iously defined as being in the top 20 % [5], or top 10 % [6], 
or top 1 % [7] of citations.
Journal Impact Factors (JIFs)
The JIF of a journal for a particular year is the average 
number of times articles from the journal have been cited 
in the past 2  years [8]. The JIF is often used to indicate 
the prestige of the journal, and publication in journals 
with a high JIF is often regarded as an indication of the 
quality of the paper itself. Consequently, there is consid-
erable pressure on academics to publish in high JIF jour-
nals [9, 10].
However, some researchers and authors have called 
for a stop to the practice of JIFs being used as a surro-
gate measure of the quality of individual research articles 
when assessing an individual scientist’s contributions, 
or in hiring, promotion, or funding decisions, and for 
research to be assessed on its own merits [11].
Research needs and prioritisation of macular research
The James Lind Alliance (JLA) Priority Setting Partner-
ships (PSPs) are part of the National Institute for Health 
Research (NIHR) [12]. The aim of the PSPs is to iden-
tify and prioritise unanswered scientific questions that 
they agree are most important, and to help ensure that 
funders of health research are aware of the priorities of 
patients and clinicians.
In 2012, the Sight Loss and Vision Priority Setting Part-
nership (SLV-PSP) surveyed patients, carers and health 
care professionals to identify and prioritise unanswered 
questions in the prevention, diagnosis and treatment of 
sight loss and eye conditions [13]. This process resulted 
in the identification of the top questions for research for 
each of the 12 eye disease/condition categories, including 
the top 10 priorities for AMD.
Aims
The aims of this report are: (1) to use bibliometric indica-
tors to review the UK’s research performance in macular 
disease conditions from 2011 to 2014 and to compare it 
with other countries producing major output in the area, 
and (2) to compare the UK’s publications with the SLV-
PSP’s top 10 priorities for AMD.
Methods
Database searching
We compiled a database of journal articles on age-related 
macular disease (AMD) and Stargardt disease. The latter 
was chosen to represent the retinal dystrophies because 
it is the commonest (there are over 100 inherited retinal 
diseases and we were not resourced to include them all 
in this study) [14]. For the sake of brevity we will refer 
to AMD and Stargardt collectively as macular disease, 
though as will be seen, the great majority of research arti-
cles relates to AMD.
Database searching for macular disease articles from the 
UK, USA, China and Germany
We searched Elsevier’s Scopus database on February 18, 
2015 using the search terms “stargardt* or age related 
macular degeneration” in the Article Title, Keyword or 
Abstract fields and limited it to publication years from 
2011 to 2014. Only document types indexed as ‘arti-
cles’ or ‘reviews’ were downloaded. Editorials, letters, 
comments and notes were excluded. The search was 
not restricted to human research, but could include, for 
example, stem cell research in animals.
All documents, without any country limit, were 
downloaded. The search was then repeated and 
refined using the Country field limits (in turn) to: (1) 
United Kingdom (2) United States (3) Germany and 
(4) China. This limited the searches to those arti-
cles with at least one author with an address in these 
countries. The searches were downloaded separately 
into Excel. The fields downloaded included; Authors, 
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Title, Year, Title of Journal, Volume, Cited by (num-
ber of citations), Affiliations of authors to institutions 
(including institution of the author for correspond-
ence), Abstract and keywords and Document Type 
(article or review).
Database searching for macular disease articles from the 
UK
An additional search, for UK authored articles only, 
of the Thomson Reuters Web of Science™ (WoS) data-
base was done to check whether any relevant records 
were missed by the Scopus search (possibly due to dif-
ferences in indexing practices and journal coverage 
between the two databases). The WoS search strategy 
was: TOPIC: (age related macular degeneration OR star-
gardt*)  AND  ADDRESS:  (north* ireland or scotland or 
england or wales) and limited to Document Types: (arti-
cle or review) and Timespan: 2011–2014.
The results from the UK authored articles for Scopus 
and WoS, were combined and duplicates removed.
Classification of UK macular disease research into AMD 
SLV‑PSP priorities
All 421 articles in the UK dataset were allocated where 
possible to the ten SLV-PSP priorities by one author 
(NW), initially based on title and abstract. In case of 
doubt the full text of articles were obtained and checked. 
Articles corresponding to the SLV-PSP priority 1 were 
sub-divided into reviews or primary research.
Percentile ranking of citations and JIFs
We obtained the top 10  % of world citations separately 
for 2011, 2012 and 2013 by downloading citations to 
macular disease articles and ranking the articles on the 
basis of citations in Excel and then selecting those articles 
in the top 10 % of journals.
To obtain the articles in the 10  % of the top ranked 
journals for 2014, we downloaded all the 2014 macu-
lar disease articles, obtained the JIFs of the journals 
they were published in, ranked them by their JIFs, and 
selected those articles in the 90th percentile. We used the 
2013 Journal Impact Factors, obtained from the Journal 
Citation Reports®, published in June 2014.
Statistical analyses
We used non-parametric statistical tests to analyse data, 
due to the non-normal distribution of the dependent 
variables, citations and JIFs. The Wilcoxon Mann–Whit-
ney Test was used to analyse the difference in citations 
between two independent groups, the Kruskal–Wal-
lis test was used to analyse the differences in citations 
between three or more groups. Spearman’s correlation 
coefficient was used to compute the correlations. Stata 
14.0 (Stata Corporation, College Station, TX, USA) was 
used for the analyses.
Results
Bibliometric analysis of UK macular disease publications 
from 2011 to 2014
We retrieved bibliographic records of 431 articles in Sco-
pus when limiting the search to the United Kingdom. 
Thirty-two articles were deleted, as macular disease was 
not the prime focus of the article, and this left 399 arti-
cles. The WoS search identified another 22 articles, giving 
a total of 421 in the final UK data set: 81 % were indexed 
as articles and 19 % as reviews.
We analysed citations only to 2011, 2012 and 2013 arti-
cles, because many 2014 articles would not have had time 
to accumulate sufficient citations at the time we did the 
searches. The citations were analysed separately for each 
of the 3 years (to account for the fact that each year had a 
different citation window).
The numbers of citations to the UK articles from 2011 
to 2013 are shown in Table 1.
The highly skewed nature of the citation distribu-
tion is evident from the data. A small number of articles 
received a large number of citations and the vast major-
ity received relatively low numbers. To adjust for the fact 
that the older articles had more time to accumulate cita-
tions, the mean number of citations per article per year 
was calculated by dividing the mean citations per article 
by the number of years between publication and collec-
tion of the citation data. The mean number of citations 
per year was 3.9 % for 2011 articles, and 4.8 and 3.8 per 
year for 2012 and 2103 respectively. The percentage of 
articles that received no citations (6.3, 8.3 and 13.4 % for 
2011, 2012 and 2013 respectively) was low (when con-
sidering the citation windows for each year), and will be 
likely to decrease over time.
Journals in which UK authors publish
The 421 UK macular disease articles were published in 
141 different journals.
Table  2 shows the top 4 journals, which published 
27.8 % of the articles. The first and third ranked journals 
(British Journal of Ophthalmology and Eye respectively) 
are from the UK and the other two (Investigative Oph-
thalmology & Visual Science and Ophthalmology) are 
based in the USA.
International collaboration
Forty-nine percent of articles were from international 
collaborations, with the number of countries ranging 
from 2 to 12. The most frequent collaborating country 
was the USA (22.3 %) followed by Germany (11.6 %), and 
Australia (7.1 %). Seventy-two percent of articles had the 
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corresponding author based in the UK. The highest pro-
portion of non-UK corresponding authors were the USA 
(10.9 %) and Germany (4.3 %).
Correlation between JIFs and citations
We examined the Spearman’s correlation between cita-
tions and JIFs for 2011, 2012 and 2013. In those years, 
92 % (285 of 311) articles were in journals with a JIF. The 
results in Table 3 show that the strength of the relation-
ship between citations and JIFs is highly statistically sig-
nificant for all years, but varies over the 3  years. There 
is a weak correlation for 2012 (rho = 0.3526), and mod-
erate correlations for 2011 (rho  =  0.4635), and 2013 
(rho = 0.6036).
Comparing UK macular disease output and citations 
with other countries
The Scopus searches for macular disease articles world-
wide from 2011 to 2013 retrieved 3262 articles. The four 
countries with the highest output (USA, UK, China and 
Germany) produced 64 % of the world’s output of macu-
lar disease research that we identified from 2011 to 2013. 
The world share of citations for these four countries was 
calculated and compared to their share of total citations, 
shown in. It can be seen that the USA, UK and Germany 
have higher percentage of the world share of citations 
than their share of the world output of articles, and are 
performing above the world average in terms of citations. 
China has a lower proportion of citations than articles, 
and on this measure is performing less well (Table 4).
Proportion of UK Authors publications in highly cited 
publications
We looked at the proportion of UK authored papers 
included in the top 10 % of the world’s most cited macu-
lar disease articles. The total numbers of macular disease 
articles in the Scopus database were 1007 in 2011, 1121 
in 2012, and 1139 in 2013 respectively. The numbers of 
citations needed for an article to be in the top 10  % of 
world citations in macular disease for these years were 
28, 20 and 11 respectively.
Table  5 shows the proportion of highly cited publica-
tions with a UK author for 2011, 2012 and 2013, the UK’s 
overall article share for each year, and the ratio of highly 
cited articles to article share. It shows that in 2011, 2012 
and 2013, UK authors’ share of the highly cited publica-
tions were 1.37, 1.88 and 1.78 times respectively greater 
than their share of world articles in macular disease.
The highly cited articles with UK authors comprised 
76 % (41/54) primary research (mainly concerning treat-
ment and pathophysiology) and 24 % review articles.
Articles in the top 10 % of JIFs in 2014 from UK authors
The 1135 worldwide macular disease articles published in 
2014 journals were ranked by JIF. Eighty percent (906 of 
1135) were in journals with a JIF, and 229 were in jour-
nals with no JIF. If we assume that in all articles with no 
Table 1 Citations to UK publications for 2011, 2012 and 2013
Mean citations for all years, Mean per year overall mean divided by the number of years in which citations were possible
Year Number of articles Number of citations Percentage uncited (%)
Median IQR Mean Range Mean per year
2011 96 9.0 4–17.5 15.4 0–128 3.85 6.3
2012 96 7.5 3–16.5 14.4 0–196 4.80 8.3
2013 119 4.0 2–8 7.6 0–96 3.80 13.4
Table 2 Top 4 journals in which UK MD articles were pub-
lished
Journal Number Percentage JIF
British Journal of Ophthalmology 33 7.8 2.809
Investigative Ophthalmology  
and Visual Science
31 7.4 3.661
Eye 29 6.9 1.897
Ophthalmology 24 5.7 6.170
Table 3 Correlation between citations and JIFs
Number of articles Correlation coefficient P value
2011 85 0.4635 <0.0001
2012 91 0.3526 0.0006
2013 109 0.6036 <0.0001
Table 4 Citations versus output from 2011 to 2013 in mac-
ular disease research for USA, UK, Germany and China
The ratio in the last row is the ratio of proportions of outputs and citations
USA UK China Germany
Proportion of world output 36.8 % 9.7 % 9.3 % 8.4 %
Proportion of world citations 54.9 % 14.2 % 6.8 % 10.8 %
Ratio of citations to output 1.49 1.46 0.73 1.29
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JIF, that JIF = 0, and rank them on their percentiles based 
on JIF we find that the JIF needed to be in the top 10 % of 
journals 5.939. The mean JIF was 2.802 and median was 
2.512.
We found that in 2014, 13.2  % of articles in journals 
ranked in the top 10 % of JIFs in macular disease had a 
UK author. UK authors’ world share of macular disease 
articles for 2014 was 9.9 %.
Matching UK macular research to the sight loss and vision 
priority setting partnerships (SLV‑PSP)
We matched the set of 421 UK publications on macu-
lar disease from 2011 to 2104 against the SLV-PSP pri-
orities for AMD. The results are in Table  6 (note that 
the numbers added up to 423 as there were 2 articles 
that belonged to both the categories ranked 5 and 6). 
Thirty-four percent of the publications did not fit any 
of the SLV-PSP priorities, as they did not include inva-
sive treatment of wet AMD in their list. Only 8 % of the 
publications were on the top priority of the SLV-PSP list, 
which was treatment to stop dry AMD progressing and/
or developing into wet AMD. Forty-four percent of publi-
cations addressing the top priority were primary research 
and 66 % were reviews.
The second priority, ‘What is the cause of AMD?’, had 
23  % of the publications, largely because of the amount 
of research into the genetics of AMD. This category was 
defined by the SLV-PSP as including whether the genetic 
factors responsible for the development or progres-
sion are known. Studies of genes comprised 45 articles, 
the biggest component of this group. It could be argued 
that genes are not the cause of AMD, but merely a fac-
tor resulting in susceptibility to it. The real causes remain 
to be determined. Similarly we included 19 studies on 
the role of complement under group 2, but this could be 
more a mechanism of disease triggered by the primary 
cause. It could be argued that the gene studies belong 
under group 5 (predictors) or group 7 (factors influenc-
ing progression).
If we take out the gene and complement studies from 
group 2, and take into account that some of the remain-
ing articles are reviews, the body of literature on causes 
of AMD in the dataset begins to look rather sparse.
The third and fourth ranked PSP priorities, prevention 
of AMD and ways of restoring sight loss, matched only 
two and one publications respectively.
Discussion
We performed a bibliometric analysis of UK macular 
research from 2011 to 2014, and compared UK perfor-
mance to the other leading countries in macular research, 
i.e. the USA, Germany and China. Also, we compared the 
Table 5 Proportion of UK authors of highly cited publications compared to article share
2011 2012 2013
UK authors on highly cited articles (top 10 % by citations) 13.7 % 16.5 % 18.3 %
UK overall article share 10.0 % 8.8 % 10.3 %
Ratio of UK authors on highly cited articles to overall article share 1.37 1.88 1.78
Table 6 Comparison of published research and SLV-PSP priorities
Rank Priority Number Percentage
1 Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised? 34 8.0
2 What is the cause of AMD? 96 22.7
3 How can AMD be prevented? 2 0.5
4 Are there ways of restoring sight loss for people with AMD? 1 0.2
5 Can the development of AMD be predicted? 19 4.5
6 What is the most effective way to detect and monitor the progression of early AMD? 54 12.8
7 What factors influence the progression of AMD? 1 0.2
8 Can a non-invasive therapy be developed for wet AMD? 11 2.6
9 Can dietary factors, nutritional supplements, complementary therapies or lifestyle changes  
prevent or slow the progression of AMD?
23 5.4
10 What are the best enablement strategies for people with AMD? 11 2.6
Articles that do not match any of the JLA priorities. Most were concerned with wet AMD 144 34.0
Uncertain 1 0.2
Stargardt’s dystrophy—the SLV-PSP list was only for AMD 26 6.1
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421 UK macular disease research publications published 
between 2011 and 2014 with the SLV-PSP’s top 10 priori-
ties for AMD. The UK, USA, and Germany all performed 
above the world average in terms of citations compared 
to their article share, whereas China had a lower pro-
portion of citations than articles. The mean citations 
per article per year for UK macular disease articles from 
2011 to 2013 was 4.15. Forty-nine percent of articles were 
internationally collaborative. The UK was shown to be 
performing well, producing 9.7 % of the world’s output of 
macular disease articles from 2011 to 2013, but receiving 
14.2 % of the world’s share citations. Also, 16.2 % of the 
top 10 % of macular disease publications, ranked by cita-
tions, had a UK author. In 2014, 13.2 % of articles in jour-
nals ranked in the top 10 % of JIFs were from UK authors; 
the overall UK article share was 9.9 %.
When matching UK macular research published from 
2011 to 2014 (but performed earlier) against the priori-
ties chosen in 2013 by the Sight Loss and Vision Priority 
Setting Partnerships (SLV-PSP), we found a considerable 
difference. Only 8 % of the publications were on the top 
priority of the SLV-PSP list and 34 % of the publications 
did not fit any of the SLV-PSP priorities.
Strengths of this study
Comprehensive searches of Scopus and the WoS were 
done to identify as much as possible of the world’s schol-
arly output on macular disease, and all abstracts were 
checked by both authors. We set our bibliometric per-
formance of UK macular research in a world context, by 
comparing it to the other three top producers of research 
in this area. We also included examination of the mostly 
highly cited publications in the field, which has been rec-
ognised as a robust approach to research assessment [7, 
15].
We measured citations in early 2015 to articles pub-
lished between 2011 and 2013, thereby giving a citation 
window ranging between 2 and 4  years. Although arti-
cles will still be accumulating citations, in most fields a 
paper is thought to reach its citation peak at 3 years and 
for citations to decrease quickly thereafter [6, 16]. Liu 
and colleagues [17] examined time to citations of articles 
in 28 ophthalmology journals. They reported that there 
were few citations in the first year after publication, but a 
rapid increase later, reaching a peak in year 3.
Finally, we compared UK macular research with SLV-
PSP priorities to see how well matched the research 
needs that had been identified by consensus amongst 
patients, carers and clinicians.
Limitations of this study
Our searches done using the terms ‘age-related macular 
disease or Stargardt*’ may have missed relevant research 
if neither term was used in title, keywords or abstract 
of the article. However this would not affect interna-
tional comparisons. We did not look at other retinal 
dystrophies.
Although citations are a good indicator of research 
quality, they are not perfect. While there has been much 
debate about their meaning, they are still widely used in 
the assessment of academic performance of individuals 
and institutions [5, 7, 18, 19]. Some bibliometric studies 
exclude self-citations, but we included them in our analy-
sis, as we took the view that this is a valid scientific prac-
tice (e.g. authors providing background and building on 
their previous work) [16].
Bibliometric analysis of macular research
In this study of macular research, we found that from 
2011 to 2013 the UK produced 9.7 % of the world’s out-
put, but received on average 14.2 % of the world’s share 
citations. Overall for these years the mean number of 
citations per article was 4.15. This is compared to the 
aggregate impact factor (AIF) of 2.357 for journals in the 
Journal Citation Reports® subject category of Ophthal-
mology for 2014 (the AIF is calculated in the same way as 
the JIF but at the subject level). This reflects well on UK 
macular research and shows that it is performing above 
average compared to the world-wide average for articles 
in ophthalmology journals.
In terms of the ratio of its share of world citations com-
pared to output, for UK’s ratio of 1.46 compared favour-
ably to the USA (1.49) and Germany (1.29). However, 
China’s ratio (0.73) was the lowest of the four countries. 
This concurs with findings from a recent study by Huang 
et  al. who analysed articles published in 53 ophthalmic 
journals from 2000 to 2011, and found that despite the 
rapid increase in output, China ranked low in terms of 
citations to articles in ophthalmic journals [20].
UK authors and highly cited publications
From 2011 to 2013, UK authors had an average of 16.2 % 
of their macular disease articles in the top 10  % of the 
world’s most cited publications in this area, with only 
9.7 % of the share of articles. This over representation of 
UK authors (including those with international collabo-
ration) in the world’s top cited publications reflects well 
on UK macular disease researchers.
Our findings are consistent with those found in a 
2013 report by Elsevier on all UK research. The Elsevier 
report was commissioned by UK’s Department of Busi-
ness Innovation and Skills (BIS) to examine how the UK 
research base compares internationally and what trends 
may affect the UK’s future standing as a world-leading 
research economy [7]. They found that while the UK pro-
duced 6.4 % of global articles in 2012, its share of global 
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citations was 11.6. Also, the UK produced 15.9 % of the 
world’s most highly cited articles (defined as being in 
the top 1 %). It therefore concluded that the UK punches 
above its weight in terms of citations.
UK authors and JIFs
In 2014, 13.2  % of articles in journals in the top 10  %, 
ranked by JIF, were from UK authors, compared to the 
overall UK article share of 9.9 %, showing that UK authors 
were over-represented in these journals s, in comparison 
with their article share. Despite objections to JIFs being 
used as a surrogate measure of the paper itself [21], and 
the fact many articles in journals with high JIFs are never 
cited [6, 22, 23], publishing in a journals with a high JIF is 
nevertheless considered prestigious, and very important 
for an academic’s reputation and career advancement [9].
Uncited articles
Another indicator of performance is the proportion of 
papers that are never cited, which a report by Thomson-
Reuters uses to identify publications with no or very little 
influence [24]. We found that on this measure UK macu-
lar research did well. Larivière et  al. [25] estimated that 
the proportion of articles uncited in the medical field in 
the WoS database was 20 % after 2 years and 12 % after 
5 years. In this study, we found that the percentage of UK 
articles uncited was 6.3 % for those with a citation win-
dow of just over 4  years, and 8.3 and 13.4  % for 3 and 
2 year citation windows respectively. Therefore, UK mac-
ular research compares favourably on this indicator.
International collaboration
Our study found an international collaboration rate of 
49 % in UK macular research. The BIS report also found 
that UK researchers are highly collaborative, and in 2012 
47.6  % of all UK articles involved international collabo-
ration [7]. They noted that international research col-
laboration and researcher mobility were core to the 
maintenance and further development of the UK’s world-
leading position as a research nation, but that increased 
collaboration and research leads to a lessening of differ-
ences amongst countries [7].
Correlation between citations and JIFs
We found that the correlation between citations to the 
macular disease articles and the JIFs of the journals in 
which they appeared from 2011 to 2013 varied from low 
to moderate over the 3  years. This lack of a consistent 
and strong correlation is similar to other recent reports 
which have examined the correlation between JIFs and 
citations to articles [26–28]. Ramin et al. found that the 
number of citations correlated poorly with the impact 
factor of journals in the AMD field [28]. This provides 
further evidence against using JIFs as a proxy for citations 
to individual articles in the journal.
Comparison of research published in 2011–2014 and the 
SLV‑PSP’s research priorities
We found a considerable difference between the topics 
in the research published in 2011–2014 and the SLV-PSP 
priorities. It should of course be noted that the SLV-PSP 
report was published in October 2013, by which time 
the research documented in this report would have been 
done. The report of the SLV-PSP envisages that it will 
help funders of research into AMD to allocate research 
funding to the top priorities [3]. This assumes that 
researchers will also target those priorities, but the report 
suggests that they will be encouraged to do so and that 
future applicants for research grants should say which 
of the priorities their proposed research will address. 
The 2015 Vision 2020 funders meeting concluded that 
researchers should be made more aware of the SLV-PSP 
priorities, and that researchers should state which of the 
priorities their research would address [29].
Time will tell whether the prioritisation exercise 
affects allocation of research funds and the priorities of 
researchers. There may sometimes be a tension between 
patient priorities and the sorts of research that universi-
ties want done, but one would expect that research into 
the top SLV-PSP priorities would be attractive to univer-
sities. The balance of research will reflect the availability 
of treatments. In wet AMD there are several treatments, 
with research underway looking at how best to use them. 
In dry AMD, research is at an earlier stage.
A bibliometric study by Ramin and colleagues looked 
further back in time, at 3235 articles on AMD published 
between 1993 and 2013, identified via the Web of Science 
[28]. They found that most of the highly-cited papers 
were on genetics, treatment of wet AMD, and on the 
effects of diet and vitamins. They noted a recent increase 
in studies in biomarkers including genes.
Conclusion
In terms of publications and citations as a measure of sci-
entific quality, the UK has done well in macular disease 
research. The UK is one of the leading countries in macu-
lar research.
However the distribution of past research topics does 
not match the priorities set by the SLV-PSP in 2013, 
and future funding may encourage a different pattern of 
research.
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